Revolution Medicines, Inc.

Good day and thank you for standing by. Welcome to the Revolution Medicine's first quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Aaron Graves. Senior Director of Corporate Communications and Investor Relations. Please go ahead.

Thank you and welcome everyone to the first quarter 2024 earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer, and Jack Anders, our Chief Financial Officer. Dr. Steve Kelsey, our President of R&D, will also join us for the Q&A portion of today's call. As we begin, I would like to note that our presentation will include statements regarding the current beliefs of the company with respect to our business that constitute forward-looking statements within the meaning of the Private Security Litigation Reform Act. These statements are subject to a number of assumptions, risks, and uncertainties. Actual results may differ materially from these statements, and except as required by law, the company undertakes no obligation to revise or update any forward-looking statements. I encourage you to review the legal disclaimer side of our corporate presentation or the earnings press release, as well as all of the company's filings with the SEC concerning these and other matters. With that, I will turn the call over to Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer. Mark?

Thanks, Erin. It's good to be with you this afternoon and to provide an update on our first quarter 2024 earnings. On today's call, I'll provide a brief update on our company progress, and Jack Anders will provide highlights of our financial results before we open the line for questions. We began 2024 with ambitious goals for our pioneering RAS-on inhibitor pipeline. We provided a roadmap outlining our three strategic priorities for the year and anticipate a catalyst-rich second half of the year that has the potential to be transformative for Revolution Medicines. Our highest priority in 2024 is to advance RMC6236 into its first pivotal monotherapy trials in major cancers driven by oncogenic RAS variants. In the second half of the year, we expect to share updated clinical data from the ongoing RMC-6236 first-in-human study from each of the pancreatic ductal adenocarcinoma and non-small cell lung cancer cohorts, including durability data. Elements of these data are part of the regulatory packages supporting engagement with the FDA to determine a go-forward dose and to obtain feedback on pivotal trial designs prior to initiating each of these studies. We are currently setting the operational foundation to enable initiating these global randomized controlled registrational trials, comparing RMC6236 monotherapy to standard of care treatments in the second half of this year. We anticipate that the first of these trials to launch will evaluate RMC6236 as second-line treatment for patients with advanced pancreatic cancer, and that we will disclose the updated clinical data supporting this trial near the study launch. Similarly, we expect that the second trial to launch will evaluate RMC6236 as second-line treatment for patients with advanced non-small cell lung cancer, and that we will disclose the updated clinical data supporting this trial near its launch. We believe that initiating these trials will represent an exciting step forward for RMC6236 on behalf of patients with these common RAS-mutated cancers, and these major steps will transition Revolution Medicines to an important new stage of company maturity. Our second development priority is focused on expanding the reach of RMC6236 beyond G12X mutations into different RAS genotypes and tumor types. This work was amplified recently with an oral presentation at the AACR annual meeting and three original scientific publications in Nature and Cancer Discovery that describe the mechanistic foundations of this groundbreaking grass on multi-selective inhibitor and illustrate its compelling clinical potential. At the meeting, we also presented four clinical cases, which, while anecdotal, showed the potential for RNC62P6 to drive deep antitumor responses at tolerated doses across a wide range of oncogenic RAS genotypes beyond KRAS G12X variants we have described previously, including the NRAS isoform and oncogenic G13X and Q61S RAS variants that drive cancers for RAS-mediated drug resistance. Of further note, two of the patients described at the ACR, one with advanced pancreatic cancer and one with advanced melanoma, experienced complete responses on treatment with RMC6236, both having progressed through prior treatment. Although clearly complete responses to RMC6236 are much less common than partial responses or absence of an objective response by resist criteria, observation of complete responses in lung, pancreatic, and melanoma patients signifies the potential power of targeting RAS addiction with this compound and further motivates us to seek to expand the reach of RMC6236 into earlier lines of treatment. In some instances, we anticipate that first-line treatment with RMC6236 will be based on a combination approach. This year, we are studying several key combination regimens to determine feasibility, and to define options for first-line registration trials with drug combinations. A high-priority combination is the Ras-on inhibitor doublet of RMC-6236 plus RMC-6291, our Ras-on G12C mutant selective inhibitor, in patients with Ras-G12C solid tumors. A study of this doublet is ongoing, and we anticipate reporting initial clinical data for the combination of RMC6236 and 6291 in the second half of the year. A second combination study is evaluating RMC6236 plus pembrolizumab with or without chemotherapy in patients with advanced RAS-mutated non-small cell lung cancer, since pembro is part of most first-line standard of care regimens in this indication. We anticipate providing initial clinical data for this combination in the second half of the year. We're also happy to share today that we've initiated two new combination studies evaluating RMC6236 with current standard of care regimens in GI cancers. The first is evaluating RMC6236 in combination with standard of care chemotherapy and first-line treatment of patients with pancreatic cancer. And the second is evaluating RMC6236 with chemotherapy and first-line treatment for colorectal cancer. These two additional studies will provide us with important insights into potential first-line registrational paths as a crucial component of our development vision for RMC6236. Our third priority for the year is to qualify our first two RAS on mutant selective inhibitors in the clinic, RMC6291, our G12C selective inhibitor, and RMC9805, our G12D selective inhibitor, for late-stage development. While we continue first-in-human monotherapy studies for both of these compounds, we are initiating combination studies to explore opportunities in early-line treatment settings. The first-in-human study evaluating RMC6291 has yielded encouraging initial clinical data in second-line monotherapy treatment of patients with KRAS-G12C non-small-cell lung cancer, including those previously treated with an approved KRAS-G12C off-inhibitor and in patients with KRAS-G12C colorectal cancer who had not been previously treated with a RAS-off inhibitor. At AACR, we presented data from preclinical models in which the RAS-on inhibitor doublet RMC6236 plus RMC6291 demonstrated significant improvement in response rates and durability relative to either monotherapy. These encouraging data reinforce our hypothesis that a RAS-on doublet combining a RAS on multiselective inhibitor with a RAS on mutant selective inhibitor may deliver meaningful benefit to patients with RAS mutant cancers. As mentioned, an initial clinical study of this combination is ongoing. A clinical study of the combination of RMC6291 with pembrolizumab is also ongoing, and we anticipate disclosing initial data for RMC6291 with pembrolizumab in the first half of 2025. We also anticipate evaluating the triplet regimen comprising the RAS-on inhibitor doublet, RMC6236 plus RMC6291, with pembrolizumab for patients with RAS-mutated non-small cell lung cancer in the first-line setting. If exploration of the triplet proves supportive, it could open the path to pursuing late-stage development of a chemotherapy-free first-line treatment regimen for patients with RAS-mutant non-small cell lung cancer. Regarding RMC9805, the first RAS on G12D selective inhibitor, we presented preclinical data in the New Drugs on the Horizon session at AACR showing that RMC9805 induced deep and durable regressions in preclinical models of several KRAS G12D tumor types. As disclosed earlier this year, oral bioavailability in patients has been confirmed And we've cleared several dose levels with good tolerability and no dose-limiting toxicities reported thus far. We expect to share initial safety, tolerability, and antitumor activity data in the second half of 2024. We are also planning for our second RAS on doublet combination study, evaluating RMC6236 plus RMC9805 in patients with advanced RAS G12D mutated cancers. We also anticipate setting RMC9805 in combination with other standard of care treatments for RAS G12D tumors. Overall, we continue pursuing our ambitious plans covering a rich set of potential opportunities toward the goal of maximizing the clinical impact of our RAS-on inhibitors in monotherapy and combination treatments for patients living with RAS-addicted cancers. In the second half of the year, We anticipate launching our first registrational studies of RMC6236 for second-line treatment in two major RAS-driven cancers, qualifying potential paths forward for evaluating RMC6236 in first-line treatments for these tumors, and establishing potential opportunities for advancing our first two clinical RAS on mutant-selective inhibitors. I'll now turn to Jack Andrews, our CFO, to provide a financial update. Jack?